in-001
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 24, 2025 (NCT07210320)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Pro-epidermal growth factorImmunity, active
EGF immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07210320 | Phase 1 | Oct 24, 2025 | Insignis Therapeutics, Inc., Washington University in St. Louis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Insignis Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1